Change Language:

Esophageal squamous cell carcinoma is a malignant neoplasm arising from the stratified squamous epithelium lining the esophageal mucosa and is one of the principal histological types of esophageal cancer worldwide. It is characterized by aggressive biological behavior, with a tendency toward early infiltration of the deeper wall layers, longitudinal extension along the esophageal axis, and lymph-node metastasis, facilitated by the extensive submucosal lymphatic drainage network that permits craniocaudal spread even when lesions appear limited. Anatomically, squamous cell carcinoma may arise in any segment of the esophagus, but it has a predilection for the middle and upper segments, in contrast to adenocarcinoma, which more commonly affects the distal segment and gastroesophageal junction. The global epidemiological pattern shows a marked geographical gradient, with areas of extremely low incidence and regions in which squamous cell carcinoma constitutes a major public-health emergency; this heterogeneity reflects profound differences in patterns of exposure to risk factors such as tobacco, alcohol, dietary habits, socioeconomic conditions, and predisposing comorbidities.

The natural history of esophageal squamous cell carcinoma is characterized by multistep progression along the dysplasia–carcinoma in situ–invasive carcinoma sequence, with gradual accumulation of genetic and epigenetic alterations in the setting of chronic mucosal injury. In the early stages, lesions may be confined to the mucosa or submucosa and may appear subtle endoscopically, whereas progression produces exophytic, ulcerated, or stenosing lesions that cause overt symptoms. Clinical presentation is often late because the high distensibility of the esophagus allows substantial tumor growth before swallowing disorders occur; consequently, a significant proportion of patients are diagnosed with locally advanced or metastatic disease, with an unfavorable prognosis. Diagnosis and staging require a structured pathway integrating endoscopy with multiple biopsies, endoscopic ultrasound to define depth of invasion and regional lymph-node status, cross-sectional imaging, and, in selected cases, metabolic assessment with PET.

Treatment of esophageal squamous cell carcinoma is typically multimodal and includes combinations of surgery, radiotherapy, and systemic therapies, whose sequence and intensity vary according to stage, the patient’s general condition, tumor location, and available resources. In high-volume centers, management is undertaken by multidisciplinary teams including oncologists, esophagogastric surgeons, radiation oncologists, endoscopists, dietitians, and rehabilitation specialists, with the aim of balancing oncological control, preservation of function, and quality of life. Despite advances in staging, patient selection, and combined-treatment protocols, esophageal squamous cell carcinoma remains associated, particularly in advanced stages, with relatively modest five-year survival rates, making reduction of exposure to risk factors, early diagnosis, and optimization of therapeutic pathways priorities.

The epidemiology of esophageal squamous cell carcinoma is characterized by marked geographical heterogeneity and very pronounced differences in incidence, mortality, and histological-type distribution compared with other forms of esophageal cancer. Globally, esophageal cancer consistently ranks among the leading causes of death from gastrointestinal malignancies, but the proportion represented by squamous cell carcinoma rather than adenocarcinoma varies considerably according to geographical area, level of economic development, and patterns of exposure to risk factors. In many regions of Asia, Africa, and Latin America, squamous cell carcinoma remains by far the predominant histological type and contributes substantially to overall cancer mortality, whereas many Western countries have experienced a progressive epidemiological shift toward distal and gastroesophageal junction adenocarcinoma over several decades, related to the different distribution of smoking, alcohol consumption, obesity, and gastroesophageal reflux. This transition is not uniform and produces important differences even within the same continent, between urban and rural areas, socioeconomic subgroups, and different ethnic groups, with persistent high-incidence clusters in settings that are otherwise at low overall risk.

The so-called “esophageal cancer belt”, extending from northern China through Central Asia to parts of Iran and neighboring countries, is the paradigm of areas at extremely high risk for esophageal squamous cell carcinoma. In these regions, incidence reaches some of the highest levels worldwide and the tumor often affects relatively young individuals living in conditions of marked socioeconomic deprivation, malnutrition, and limited access to structured healthcare services. Some regions of East and southern Africa also show high incidence rates, frequently associated with consumption of traditional alcoholic beverages, tobacco use, indoor pollution from biomass combustion, and micronutrient-deficient diets. In South America, particularly in some areas of Brazil, clusters of squamous cell carcinoma have been described and are probably related to specific dietary habits, including repeated consumption of beverages at high temperatures. In Western Europe and North America, the incidence of squamous cell carcinoma has progressively declined in parallel with reductions in smoking and high-proof alcohol consumption, although it remains relevant in high-risk population subgroups.

Demographically, esophageal squamous cell carcinoma shows a clear male predominance, with male-to-female ratios exceeding 3:1 in many series, reflecting greater exposure to the main modifiable risk factors, particularly tobacco and alcohol. In Western countries, diagnosis occurs most commonly in the sixth and seventh decades of life, whereas in regions of extremely high incidence the disease may arise at a younger age, especially when environmental and dietary exposures begin early and persist over time. Ethnic differences in risk distribution have also been documented, suggesting an interaction among genetic factors, socioeconomic conditions, and inequalities in access to care. Overall prognosis remains unfavorable compared with many other gastrointestinal malignancies, largely because the disease is frequently identified at an advanced stage.

Among risk factors, the most important determinant is chronic consumption of tobacco and alcohol, whose synergistic association is the principal causal factor for esophageal squamous cell carcinoma in middle- and high-income countries. Smoking exposes the esophageal epithelium to numerous carcinogens, including polycyclic aromatic hydrocarbons and nitrosamines, which cause cumulative DNA damage in basal cells. Ethanol, through its reactive metabolite acetaldehyde, exerts a direct cytotoxic effect on the mucosa and promotes formation of DNA adducts, in addition to potentiating the action of other carcinogens. Combined tobacco and alcohol exposure increases risk far more than either factor alone, particularly when consumption is heavy and prolonged. Individual susceptibility is modified by genetic polymorphisms in enzymes involved in ethanol and aldehyde metabolism, especially ADH and ALDH; variants that cause acetaldehyde accumulation are associated with particularly high risk in some Asian populations. In this context, reducing or eliminating tobacco and alcohol consumption is the cornerstone of primary prevention of esophageal squamous cell carcinoma in industrialized countries.

Alongside behavioral factors, numerous dietary and environmental determinants play an important role, especially in high-incidence areas. Habitual consumption of very hot beverages, such as tea and traditional infusions consumed at high temperatures, has been associated with increased risk, probably because chronic thermal injury to the esophageal mucosa promotes persistent inflammation and greater vulnerability to chemical insults. Diets low in fruit, vegetables, and antioxidant micronutrients such as vitamins A, C, and E, folate, selenium, and zinc have been associated with higher risk in many populations, suggesting that deficiency of nutrients involved in protection from oxidative stress and DNA-repair processes may facilitate mutation accumulation. In several high-risk rural settings, substantial exposure to nitrosamines and other potentially carcinogenic substances present in preserved, smoked, or mycotoxin-contaminated foods has been documented. Improving dietary quality, food preservation, and access to essential micronutrients is therefore a fundamental component of primary prevention in regions with high incidence.

Several pre-existing esophageal disorders are additional predisposing factors. Achalasia, characterized by aperistalsis and chronic stasis of esophageal contents, is associated with an increased risk of squamous cell carcinoma after many years of disease, probably because of the combination of food stasis, chronic inflammation, and mechanical trauma. Caustic strictures following ingestion of corrosive substances are a classic substrate for the development of squamous cell carcinoma decades after the initial event, in relation to cicatricial remodeling and persistent inflammation. Plummer–Vinson syndrome, historically associated with an increased risk of squamous tumors of the upper aerodigestive tract, is now uncommon in industrialized countries. Previous radiotherapy to the chest or neck may also increase the risk of secondary esophageal tumors in relation to the cumulative absorbed radiation dose.

Rare genetic conditions are also associated with a particularly high risk of esophageal squamous cell carcinoma. Esophageal tylosis, characterized by hereditary palmoplantar keratoderma, is one of the best-known examples and is associated with a dramatically higher cumulative risk of esophageal cancer than in the general population. Other syndromes involving genomic instability or defective DNA-repair mechanisms, such as Fanconi anemia and Bloom syndrome, are associated with an increased incidence of squamous tumors even at a relatively young age. Familial clustering of esophageal carcinoma that cannot be fully explained by shared environmental factors has also been observed in many areas of extremely high incidence, suggesting a component of genetic susceptibility that remains incompletely understood.

The role of viral infections, particularly human papillomavirus, remains controversial. Viral DNA has been detected in esophageal squamous cell carcinoma samples in some series, especially in specific geographical areas, but the overall evidence does not support considering HPV a universally recognized risk factor for this neoplasm. By contrast, chronic exposure of the upper aerodigestive tract to the same carcinogens is a well-established concept, with an increased risk of multiple tumors in individuals heavily exposed to tobacco and alcohol. Socioeconomic factors such as low educational level, poverty, poor oral hygiene, household use of solid fuels, and limited access to healthcare services also help sustain high incidence in some populations and hinder effective primary-prevention interventions.

Taken together, these elements define a setting in which the risk of esophageal squamous cell carcinoma results from a complex interaction among behavioral, dietary, environmental, pathological, and genetic factors, whose relative weight varies substantially across geographical and socioeconomic contexts. Identifying and modifying preventable determinants is the fundamental prerequisite for reducing disease incidence at the population level.

Unlike other gastrointestinal malignancies, population-based screening programs are not recommended for esophageal squamous cell carcinoma in areas of low or intermediate incidence. This reflects its relatively low frequency in the general population, the absence of noninvasive tests with adequate diagnostic accuracy, and the unfavorable cost-effectiveness of widespread endoscopic screening. In selected settings, however, early diagnosis is clinically important and is pursued through targeted strategies for populations whose risk is clearly above average.

In areas of extremely high incidence, particularly in parts of Central Asia, China, and Iran, early-detection programs based on endoscopy with Lugol chromoendoscopy have been developed. This method highlights abnormalities of the squamous mucosa, including dysplasia and superficial lesions, in individuals who often have few symptoms. Systematic use of these programs has shown that diagnosis can be made earlier than in routine clinical practice, but they require substantial resources, dedicated endoscopic expertise, and careful selection of the target population, limiting their applicability in low-incidence settings.

In Western countries, endoscopy is not indicated for screening the general population but has a role in the surveillance of high-risk individuals. An important example is patients with longstanding achalasia, in whom the cumulative risk of squamous cell carcinoma increases over time. Periodic endoscopic monitoring is commonly adopted in these cases and is tailored to disease duration, age, and clinical course, although universally accepted recommendations regarding the optimal interval are lacking.

Similar attention is given to individuals with previous caustic strictures, in whom neoplastic transformation may occur many years after the initial event. Long-term endoscopic surveillance is generally recommended for these patients, with particular attention to scarred areas and segments of chronic stenosis. In patients with esophageal tylosis or other inherited high-risk conditions, regular endoscopic assessment is an integral part of clinical management and is often started early.

Another setting for surveillance involves individuals with chronic exposure of the upper aerodigestive tract to the same carcinogens, particularly patients with a history of squamous cell carcinoma of the oral cavity, pharynx, or larynx. In these individuals, endoscopic monitoring of the esophagus may be considered, especially when suggestive symptoms or persistent tobacco and alcohol exposure are present. Chromoendoscopy and advanced optical imaging techniques increase the likelihood of detecting subtle or multifocal mucosal abnormalities.

In recent years, emerging technologies have been explored, including virtual chromoendoscopy, analysis of microvascular patterns, and minimally invasive devices for esophageal cell sampling. These approaches aim to simplify and standardize early lesion detection, but they have not yet acquired an established role in routine clinical practice and remain largely confined to research settings or highly specialized centers.

Overall, screening for esophageal squamous cell carcinoma is not indicated in the general population, whereas selective surveillance of high-risk groups is a rational strategy. Its effectiveness depends on correct identification of candidates, use of appropriate endoscopic methods, and integration of monitoring into structured clinical pathways, with the aim of detecting disease at an early stage without exposing patients to unnecessary or excessive procedures.

The biology of esophageal squamous cell carcinoma develops in the setting of chronic, repeated injury to stratified squamous epithelium. Normal esophageal mucosa, organized into a proliferative basal layer and overlying layers with progressive differentiation, maintains a balance among proliferation, differentiation, and programmed cell death. Persistent exposure to harmful agents such as tobacco, ethanol, aldehydes, dietary nitrosamines, products of biomass combustion, thermal injury, and chronic inflammation produces continuous regenerative stimulation, with basal-cell hyperplasia, disruption of epithelial architecture, loss of orderly maturation, and cytological atypia. A morphological continuum is thereby established, encompassing mild, moderate, and severe dysplasia, carcinoma in situ, and invasive carcinoma. Progression along this spectrum is driven by the accumulation of mutations, epigenetic alterations, and tissue remodeling that compromise epithelial homeostasis and promote infiltrative biological behavior.

A crucial step in progression is basement-membrane disruption, which allows neoplastic cells to extend beyond the epithelium into the lamina propria and submucosa and subsequently into the deeper wall layers. Esophageal anatomy contributes to the propensity for lymphatic spread: the submucosa contains abundant longitudinal lymphatic vessels, facilitating lymph-node involvement even when the lesion appears macroscopically limited. In this setting, depth of infiltration and lymphatic-vessel involvement reflect the invasive capacity of the tumor and its interaction with the stromal compartment.

At the genetic level, esophageal squamous cell carcinoma shows marked genomic instability, with point mutations, amplifications, deletions, and complex chromosomal rearrangements. TP53 mutation is among the most frequent alterations and is often already detectable in dysplastic lesions, consistent with an early role in loss of genomic surveillance, defective cell-cycle arrest, and reduced DNA-repair efficiency. Alterations in genes involved in squamous differentiation, including NOTCH1, NOTCH3, KLF5, and SOX2, contribute to loss of the epithelial maturation program and dysregulated proliferation. Amplifications involving genes such as CCND1, FGFR1, EGFR, and MYC sustain mitogenic signaling and increase tolerance of replicative stress. Several signaling pathways are frequently dysregulated, including PI3K/AKT, WNT, TGFβ, JAK/STAT, MAPK, and components of the Hippo cascade, with possible nuclear accumulation of YAP1 and transcriptional activation of pro-proliferative programs. Analyses of international cohorts, including those from TCGA, have demonstrated substantial heterogeneity, with patterns that may be influenced by different environmental and dietary exposures.

Alongside genetic alterations, epigenetic changes make a substantial contribution to neoplastic transformation. Hypermethylation of tumor-suppressor gene promoters, histone modifications that alter chromatin accessibility, and changes in microRNA expression involved in controlling proliferation, differentiation, and migration have been described. MicroRNAs such as miR-21 and miR-223 are often overexpressed, whereas microRNAs associated with the differentiated state of squamous epithelium, such as miR-203, tend to be reduced. These changes, combined with the action of environmental mutagens, promote the development of broad mucosal fields containing shared clonal alterations and predispose to multifocal transformation along the esophageal axis.

The tumor microenvironment participates actively in pathogenesis and progression. The chronic inflammatory infiltrate, composed of lymphocytes, macrophages, dendritic cells, myeloid-derived suppressor cells, and activated fibroblasts, creates a cytokine- and mediator-rich environment that includes IL-6, IL-1β, TNF, and TGFβ and promotes proliferation, invasiveness, and local immunosuppression. Hypoxia, common in rapidly growing tumor masses, induces HIF-1α and modulates metabolic and angiogenic programs; VEGF is one of the main mediators of angiogenesis in this setting, producing a disorganized vascular network that nevertheless supports growth. At the same time, the extracellular matrix is remodeled by metalloproteinases produced by neoplastic and stromal cells, facilitating invasion and reorganization of the connective-tissue compartment.

At the immunological level, esophageal squamous cell carcinoma is markedly heterogeneous. PD-L1 expression by tumor cells and infiltrating immune cells, variable but sometimes substantial, reflects a dynamic balance between immune activation and evasion mechanisms. Although tumor mutational burden is generally moderate, specific mutational signatures may contribute to neoantigen generation. The local immune response is often limited by functional exhaustion of CD8 T cells, with expression of PD-1 and other dysfunction markers, and by an increase in regulatory T cells. NK-cell effectiveness may also be reduced in the presence of MHC-I alterations and immunosuppressive microenvironmental factors. Integration of these elements contributes to tumor persistence and progressively more aggressive expansion.

Integrated analyses of international cohorts have proposed distinct molecular subtypes:

• proliferative subtype: characterized by high chromosomal instability, multiple amplifications, and predominance of pro-mitotic pathways.
• inflammatory subtype: characterized by marked immune infiltration, high expression of interferon-related genes, and a relatively less unstable genetic profile.
• metabolic subtype, described in some Eastern cohorts, characterized by specific adaptations of oxidative metabolism, dependence on glutaminolysis, and remodeling of lipid metabolism.

Although not systematically used in clinical practice, these profiles reflect genuine biological diversity that contributes to heterogeneity in disease behavior.

From a metabolic standpoint, neoplastic cells adopt adaptive strategies that permit growth and survival under stressful conditions. Aerobic glycolysis provides energy rapidly and generates biosynthetic intermediates; glutaminolysis supports anaplerotic pathways; fatty-acid metabolism and the ability to handle high levels of reactive oxygen species strengthen cellular resilience. Resistance to oxidative stress is supported by antioxidant programs and alternative metabolic circuits. Recent studies also suggest possible variability in susceptibility to processes such as ferroptosis, an area that is still evolving.

The histological component of esophageal squamous cell carcinoma is varied and, according to differentiation, is classified into:

• well-differentiated tumors: showing evident keratinization, keratin pearls, and intercellular bridges; moderately differentiated forms show less marked keratinization and greater architectural disorganization;
• poorly differentiated tumors: characterized by cellular pleomorphism, a high mitotic index, and an infiltrative growth pattern.
• basaloid squamous cell carcinoma: a variant with nests of small dark cells in a fibrous stroma, associated with aggressive behavior.

Immunohistochemistry supports confirmation of squamous differentiation and the differential diagnosis: p40, CK5/6, and p63 are typical markers, whereas Ki-67 provides an estimate of the proliferative fraction. Lymphatic and perineural invasion and depth of infiltration are morphological expressions of the tumor’s invasive capacity.

Preclinical models have helped clarify important aspects of the biology of esophageal squamous cell carcinoma. Organoids derived from tumor samples reproduce three-dimensional architecture and clonal heterogeneity, allowing signaling pathways and resistance mechanisms to be studied. Patient-derived xenograft (PDX) models permit functional assessment of growth and invasiveness in a complex biological setting. Single-cell sequencing techniques are defining clonal organization and interactions among cellular compartments, identifying subpopulations with stem-like properties and distinct evolutionary trajectories. Genetically engineered mouse models also make it possible to investigate the role of specific genes and pathways in maintaining the malignant phenotype.

Overall, esophageal squamous cell carcinoma emerges as a highly complex neoplasm determined by the interaction of genetic and epigenetic alterations, microenvironmental remodeling, metabolic adaptations, and immune modulation. These processes, combined with a history of chronic epithelial injury, explain its tendency to invade and its capacity to spread through submucosal lymphatic structures.

The clinical manifestations of esophageal squamous cell carcinoma arise mainly from progressive impairment of food transit, involvement of the wall and adjacent structures, and the systemic effects of disease. In the early stages, the lesion may remain confined to the most superficial layers without appreciably narrowing the lumen, which is why many patients are asymptomatic. At this stage, the diagnosis may emerge incidentally during esophagogastroduodenoscopy performed for nonspecific symptoms, unexplained iron-deficiency anemia, or clinical surveillance of individuals with predisposing conditions. The silent nature of onset is critical because recognition often occurs only after the tumor has already caused substantial functional impairment.

The cardinal symptom is dysphagia, caused by luminal narrowing or segmental motility impairment induced by neoplastic infiltration. Initially, dysphagia is typically intermittent and mainly affects solid foods, with a sensation that the bolus is slowing or stopping behind the sternum and a frequent need to drink to facilitate its passage. Esophageal distensibility nevertheless allows prolonged compensation, so the disorder may not appear until stenosis is pronounced. Some patients also experience odynophagia, described as burning or stabbing pain on swallowing, sometimes radiating posteriorly or toward the neck, which further reduces food intake.

As the condition evolves, dysphagia tends to worsen progressively, first affecting solid foods, then semisolid consistencies, and finally liquids. Patients change their eating habits by eliminating firmer foods and moving to soft or semiliquid diets. This often results in substantial weight loss, caused both by reduced caloric intake and tumor-associated metabolic changes. Retrosternal pain may be constant or triggered by swallowing and is sometimes interpreted as a cardiac disorder or a more common benign condition, contributing to delayed assessment. Regurgitation of undigested food, sialorrhea, halitosis, and a sensation of stasis may occur, particularly when luminal retention is substantial.

Symptoms may vary according to the site of the neoplasm along the esophagus because of the different anatomical relationships of the cervical, middle thoracic, and distal segments:

• cervical and proximal esophageal tumors: may be associated with hoarseness and progressive dysphonia due to involvement of the recurrent laryngeal nerve, with irritative cough and difficulty controlling secretions, increasing the risk of aspiration;
• middle-third tumors: more often associated with pressure-like or burning retrosternal pain and a sensation of chest constriction;
• distal-third and gastroesophageal junction tumors: may present with heartburn, acid regurgitation, and belching, mimicking dyspepsia or reflux disease.
• at any site, the combination of worsening dysphagia, odynophagia, and unintentional weight loss is an important clinical warning sign requiring prompt assessment.

Local progression with invasion of adjacent structures produces more complex presentations. Involvement of the trachea and main bronchi may cause persistent cough, dyspnea, noisy breathing, and recurrent respiratory infections. Formation of tracheoesophageal or esophagobronchial fistulas is one of the most serious complications and presents with coughing and choking during attempts to eat, repeated aspiration, and aspiration pneumonia. Extension to the pericardium or myocardium may cause atypical chest pain, pericardial effusion, and arrhythmias, progressing to tamponade in extreme cases. Pleural involvement may be associated with pleuritic pain and dyspnea, whereas phrenic-nerve involvement may cause persistent hiccups or worsening dyspnea due to unilateral diaphragmatic paralysis. In rare cases, involvement of the cervical sympathetic chain may cause Horner syndrome with ptosis, miosis, and anhidrosis.

Ulcerated tumor mucosa may bleed, causing progressive iron-deficiency anemia with pallor, tachycardia, reduced exercise tolerance, and headache. More substantial bleeding presents with hematemesis or melena, whereas erosion of major vascular structures may cause rapidly fatal massive hemorrhage. Systemically, advanced disease is often associated with cancer cachexia, including loss of muscle mass and adipose tissue, marked fatigue, anorexia, and functional deterioration.

Regional lymph-node spread may become clinically apparent when lateral cervical or supraclavicular lymph nodes are involved, including Virchow’s node. Distant metastases cause symptoms determined by the organ involved, such as bone pain and pathological fractures from skeletal lesions, dyspnea and chest pain from pulmonary lesions, painful hepatomegaly and jaundice from hepatic metastases, or headache, focal neurological deficits, and seizures from brain involvement. Widespread dissemination is often accompanied by rapid weight loss, marked fatigue, and a substantial decline in physical performance.

A minority of patients may develop paraneoplastic syndromes with dermatological, neurological, endocrine, or rheumatological manifestations. Reported conditions include dermatomyositis, peripheral neuropathies, coagulation disorders, and electrolyte abnormalities such as hypercalcemia. Although uncommon overall, their occurrence together with esophageal symptoms and weight loss should prompt a comprehensive diagnostic assessment.

Physical examination may reveal evidence of nutritional impairment, including reduced muscle mass, dry skin, loss of subcutaneous fat, and signs of hypoalbuminemia. Cervical or supraclavicular lymphadenopathy is relatively common in advanced disease. Signs of anemia, diminished breath sounds in the presence of pleural effusions, and findings consistent with aspiration pneumonia when a fistula is present may coexist. The typical presentation is that of a middle-aged or older patient with prolonged exposure to smoking and chronic alcohol use, reporting worsening dysphagia, weight loss, fatigue, and retrosternal pain.

The diagnostic workup for esophageal squamous cell carcinoma begins with concrete clinical suspicion and proceeds through a sequence of investigations aimed, in order, at histological confirmation of the neoplasm, assessment of alternative diagnoses, and definition of disease extent before formal staging is introduced. Suspicion typically arises in the presence of progressive dysphagia, odynophagia, unintentional weight loss, unexplained iron-deficiency anemia, persistent retrosternal pain, regurgitation of undigested food, or recurrent respiratory symptoms such as postprandial cough and aspiration pneumonia, especially in individuals with risk factors including smoking, chronic alcohol use, previous caustic ingestion, longstanding achalasia, or a history of head and neck malignancies. In this context, the objective of the first clinical encounter is to recognize a suggestive presentation promptly and refer the patient for timely endoscopic assessment, avoiding low-yield diagnostic steps that may delay etiological definition.

The reference investigation for diagnosis is esophagogastroduodenoscopy, which is the first truly decisive specialist examination. In accordance with major international guidelines, the contemporary approach uses EGD as the first-line test, without requiring a barium study as a mandatory preliminary step, except in selected situations such as high anesthetic risk or extremely tight stenoses that make passage of the endoscope uncertain. Endoscopy should be performed with high-definition equipment and include a systematic description of the lesion: site measured from the incisors, longitudinal extent, circumferential involvement, macroscopic morphology (exophytic, ulcerated, infiltrative, stenosing, or flat), degree of luminal obstruction, and traversability. Complete inspection of the esophagus is also essential to search for synchronous lesions and recognize suspicious mucosal areas in a background of chronic injury.

In squamous cell carcinoma, image-enhanced endoscopic methods are often an integral part of the examination. Lugol chromoendoscopy highlights so-called Lugol-voiding lesions, which correlate with advanced dysplasia or superficial carcinoma. Techniques such as NBI and optical magnification permit assessment of the microvascular pattern, including intrapapillary capillary loops, and improve delineation of pathological areas. Systems such as BLI or FICE can help define mucosal margins and reveal multifocal areas not immediately apparent with conventional endoscopy alone.

During the same procedure, multiple biopsies are obtained and constitute the cornerstone of definitive diagnosis. Numerous representative samples should be taken from different areas of the lesion, including its margins and central portions, to reduce the risk of false-negative results due to superficial necrosis or heterogeneity. When a tight stenosis prevents passage of a standard instrument, small-caliber endoscopes may be used to reach the narrowest segment and obtain adequate samples. If repeated biopsies remain nondiagnostic despite a highly suspicious endoscopic appearance, macrobiopsies or diagnostic endoscopic procedures such as endoscopic mucosal resection or submucosal dissection may be considered, particularly for superficial lesions, to obtain a larger and more informative specimen.

Histopathological analysis of the samples provides the definitive diagnosis of squamous cell carcinoma. Hematoxylin and eosin staining shows disorganized squamous epithelial architecture, cytoplasmic keratinization, keratin pearls, intercellular bridges, nuclear pleomorphism, increased mitotic activity, and stromal infiltration. The pathologist determines the degree of differentiation, assesses necrosis and vascular or perineural invasion, and, when morphology is nonspecific, uses immunohistochemistry with markers such as p40, p63, and CK5/6 to confirm squamous differentiation and distinguish the lesion from adenocarcinoma, undifferentiated carcinoma, neuroendocrine neoplasms, or lymphoma. When secondary involvement of the esophagus by squamous cell carcinoma from another site is plausible, integration with the clinical context and comparison with any known malignancy guide correct attribution of the primary site.

According to major international guidelines, a minimum core of information must be available before a diagnosis of esophageal squamous cell carcinoma can be considered established and clinical decisions made; these elements are not formal “diagnostic criteria,” but represent the essential requirements for a reliable diagnosis:

Elements required to establish a diagnosis of esophageal squamous cell carcinoma

• Endoscopic documentation of a macroscopically suspicious esophageal lesion in a patient with a compatible clinical presentation.
• Multiple representative biopsies of the lesion, repeated or supplemented by mucosal resection when initial samples are inconclusive.
• Histological demonstration of carcinoma with squamous differentiation and typical morphological features.
• Immunohistochemical support with squamous markers in poorly differentiated cases or when the differential diagnosis is complex.
• Exclusion, based on the clinical context and complementary investigations, of metastatic squamous cell carcinoma from another site.

After histological confirmation, the differential diagnosis must be addressed in a structured manner. Among neoplastic conditions, it is essential to distinguish squamous cell carcinoma from other esophageal and mediastinal neoplasms, particularly adenocarcinoma of the distal esophagus and gastroesophageal junction, using the site, clinical context, and immunophenotype. Neuroendocrine carcinoma, small-cell carcinoma, primary or metastatic melanoma, esophageal gastrointestinal stromal tumors, and esophageal lymphoma must also be considered; morphology and immunohistochemistry generally allow clear discrimination. Among non-neoplastic conditions, dysphagia with stenosis may result from reflux-related peptic strictures, post-caustic scarring, radiotherapy sequelae, Schatzki rings, eosinophilic esophagitis, achalasia, or primary motility disorders; in these cases, endoscopy with targeted biopsies, esophageal manometry, and, when appropriate, a barium study allow correct definition. Extrinsic compression by mediastinal masses, aneurysms, or cardiomegaly must also be considered: endoscopy may show intact mucosa with luminal deformation, while cross-sectional imaging clarifies the extramural nature of the obstruction.

Once the diagnosis has been established, investigations focus on assessment of disease extent. Endoscopic ultrasound (EUS) permits detailed evaluation of the layers of the esophageal wall and periesophageal tissues, estimating depth of infiltration and identifying suspicious regional lymph nodes according to morphological and ultrasonographic criteria. When a lymph node appears suspicious, EUS-guided fine-needle aspiration (FNA) provides cytological material to confirm or exclude neoplastic involvement. In parallel, contrast-enhanced computed tomography of the chest and abdomen is required for an overall assessment of locoregional extension and distant disease, including relationships with mediastinal structures and the main metastatic sites. 18F-FDG PET provides functional information useful for identifying metabolically active foci not apparent on CT alone, especially in extraregional lymph nodes or sites such as bone, adrenal glands, and liver when lesions remain small, and helps distinguish neoplastic involvement from reactive conditions. For tumors of the upper third or in the presence of respiratory symptoms, bronchoscopy is indicated to assess airway involvement and identify fistulas. For cervical tumors or dysphonia, laryngoscopy documents vocal-cord motility abnormalities and defines recurrent laryngeal nerve involvement.

In summary, the diagnostic assessment of esophageal squamous cell carcinoma follows a practical sequence: recognition of clinical suspicion; esophagogastroduodenoscopy with advanced imaging and multiple biopsies; histological confirmation with immunohistochemical support when needed; definition of the differential diagnosis; and then assessment of disease extent by endoscopic ultrasound, computed tomography, PET, and, when indicated, bronchoscopy and laryngoscopy.

The staging of esophageal squamous cell carcinoma summarizes the information obtained during the diagnostic workup and allows the anatomical extent of disease to be described in a standardized manner, localized forms to be distinguished from advanced disease, and prognostic guidance to be provided. The international reference is the eighth edition of the AJCC/UICC TNM system, which includes clinical staging (cTNM), pathological staging after surgery without preoperative treatment (pTNM), and pathological staging after preoperative therapy (ypTNM). The system is based on data from the Worldwide Esophageal Cancer Collaboration and incorporates variables that influence prognosis in squamous cell carcinoma even with the same T, N, and M categories, including tumor location and histological grade, while retaining stage groupings distinct from those for adenocarcinoma.

Clinical cTNM staging is constructed by integrating endoscopic ultrasound findings for depth of infiltration and regional lymph-node assessment, with sampling when appropriate, contrast-enhanced computed tomography of the chest and abdomen for locoregional extent and distant disease, and 18F-FDG PET to identify metabolically active foci not apparent on CT alone and better characterize suspicious lymph nodes. For upper-third tumors or respiratory symptoms, bronchoscopy is used to document airway involvement or fistulas, while laryngoscopy helps define involvement of laryngeal structures and vocal-cord mobility in cervical tumors or dysphonia. The information collected is assigned to T, N, and M categories and then to clinical stage groups, which provide a practical summary of disease extent.

In squamous cell carcinoma, the principal prognostic determinants remain depth of mural infiltration, number of metastatic lymph nodes, and presence of distant metastases. The TNM system organizes anatomical progression along a spectrum from intraepithelial and superficial lesions to disease with distant involvement. Conceptually, stage groups describe progression from the mucosa into deeper layers and subsequently to lymph-node and systemic spread.

In simplified terms, the main stage groups for esophageal squamous cell carcinoma can be summarized as follows:

Main stage groups in esophageal squamous cell carcinoma (general concept, AJCC/UICC 8th edition)

• Stage 0: intraepithelial neoplasia or carcinoma in situ confined to squamous epithelium without invasion of deeper layers.
• Stage I: invasive tumor limited to the mucosa or submucosa without lymph-node or distant metastases (T1 with N0 and M0), with some grouping variants that may include small tumors with favorable characteristics.
• Stage II: disease infiltrating the muscularis propria or adventitia without extensive lymph-node involvement, or more superficial lesions with limited lymph-node involvement.
• Stage III: a more locally extensive tumor and/or broader lymph-node involvement without distant metastases, producing a complex anatomical pattern that remains locoregionally confined.
• Stage IV: presence of distant metastases (M1), irrespective of T and N categories.

When a surgical specimen is available without preoperative treatment, pathological pTNM staging refines prognostic assessment through direct measurement of depth of infiltration, number of lymph nodes examined and involved, resection-margin status, and presence of vascular or perineural invasion. In patients treated preoperatively, ypTNM staging describes the extent of residual disease and distinguishes complete pathological responses from cases with more extensive persistent tumor. In general, a marked reduction in residual disease is associated with improved outcome, whereas persistent lymph-node involvement or a substantial residual mural component maintains an unfavorable prognostic profile even after technically radical resection.

Survival curves show a close relationship between stage and outcome. In contemporary cohorts selected for surgical treatment, overall five-year survival is often around 40–50 percent, but varies substantially among stage groups. Clinical series report very high values for intraepithelial and early disease, a progressive decline through intermediate stages, and markedly lower survival in metastatic disease. Population-based analyses, which include all presentations and treatment approaches, show lower overall five-year survival than surgical cohorts, reflecting the frequent diagnosis at an advanced stage. Diagnosis while disease is localized and the ability to achieve complete resection are central determinants of a favorable outcome.

In addition to TNM, several additional prognostic factors modify individual risk. Important tumor-related factors include histological grade, longitudinal extent of the lesion, and especially the number of metastatic lymph nodes, with interest also in the ratio of positive to examined lymph nodes. Vascular invasion, perineural infiltration, and resection-margin status are associated with differences in outcome. In patients receiving radiotherapy, the three-dimensional tumor volume used in planning has been correlated with local control and survival, with larger volumes associated with a higher risk of failure.

Patient-related factors, including performance status, nutritional status, and cardiovascular, respiratory, or metabolic comorbidities, significantly influence prognosis both through their effect on treatment tolerability and as indicators of physiological reserve. Indices such as the Prognostic Nutritional Index, the Geriatric Nutritional Risk Index, and scores based on albumin and systemic inflammatory markers, including the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios, have been associated with survival differences within the same stage. Pretreatment weight loss and CT-documented sarcopenia also correlate with unfavorable outcomes in many cohorts, underscoring the importance of biological frailty in addition to anatomical disease extent.

In recent years, tissue and molecular biomarkers with potential prognostic value have been studied, including markers of signaling pathways, invasion, metabolism, and immune interaction, such as PD-L1 expression. Despite numerous reported associations, none has replaced TNM in routine practice, and the most common approach remains integration of the anatomical system with clinical and nutritional parameters, often incorporated into composite prognostic models.

Overall, staging of esophageal squamous cell carcinoma is an integrated process combining anatomical extent, histological characteristics, and the patient’s general condition. High long-term survival can be observed in early disease, whereas in more advanced forms prognosis remains strongly influenced by lymph-node burden and the ability to achieve disease control. In metastatic disease, overall survival remains limited and clinical attention focuses on symptom control and preservation of quality of life.

Treatment of esophageal squamous cell carcinoma requires a genuinely multimodal approach in which interventional endoscopy, surgery, radiotherapy, chemotherapy, and immunotherapy are integrated and sequenced according to disease extent, site, biological characteristics, comorbidities, and patient preferences within a pathway shared by an experienced multidisciplinary team. In practical terms, strategies span a continuum: endoscopic treatment for very early disease; combined curative-intent therapies for resectable forms; definitive chemoradiotherapy when surgery is not indicated or feasible; and systemic treatment for recurrent or metastatic disease, always accompanied by nutritional support and symptom control.

For very early tumors confined to the mucosal layer (Tis/T1a), without lymphovascular invasion, submucosal infiltration, or other high-risk histological features, endoscopic resection is an established curative option. Endoscopic mucosal resection is indicated for relatively limited lesions, whereas endoscopic submucosal dissection (ESD) allows en bloc resection of larger lesions and provides better assessment of margins and biological risk. Selection requires accurate staging, particularly to estimate depth of infiltration and possible lymph-node involvement. When examination of the specimen shows clear margins, invasion confined to the mucosa, and no adverse factors, resection may be considered definitive and followed by close endoscopic surveillance. Conversely, submucosal invasion (T1b), positive or close margins, lymphovascular invasion, or perineural invasion indicate the need for additional treatment, typically surgery with lymph-node dissection, or nonsurgical approaches in inoperable patients. In selected frail individuals, a less invasive strategy may be maintained while accepting a higher risk profile after individualized assessment.

For locally advanced but potentially resectable disease, a cornerstone of Western guidelines is neoadjuvant chemoradiotherapy followed by surgery. Platinum- and fluoropyrimidine-based regimens or carboplatin plus paclitaxel are combined with radiotherapy, typically in the range of 41.4–50.4 Gy, to reduce tumor volume, increase the likelihood of R0 resection, and treat subclinical micrometastases. Reassessment after neoadjuvant treatment with appropriate imaging and clinical evaluation confirms the absence of systemic progression and allows surgery to proceed in eligible patients, while redirecting the strategy if progression or new contraindications arise.

In several Asian settings, particularly for thoracic squamous cell carcinomas, neoadjuvant chemotherapy followed by esophagectomy is established, with classic cisplatin and 5-fluorouracil regimens administered before surgery in patients with stage II–III disease. Some centers use more intensive taxane-containing regimens, balancing potential benefit against greater toxicity. The choice between neoadjuvant chemoradiotherapy and chemotherapy depends on anatomical and histological characteristics, availability of high-quality radiotherapy, institutional expertise, and the individual tolerability profile.

Surgery is a cornerstone for resectable disease, either after preoperative therapy or, in selected settings, as primary treatment. The aim is an R0 resection together with adequate lymph-node dissection. The reference procedure is esophagectomy with reconstruction, most commonly using a gastric conduit; when the stomach cannot be used, colonic interposition or, in selected cases, a microvascular jejunal graft is employed. The extent of lymphadenectomy varies according to the site: two-field dissection is standard for distal tumors, whereas cervical extension may be considered for middle- and upper-third squamous cell carcinomas, especially in experienced centers, taking into account the risk of injury to the recurrent laryngeal nerves and the resulting functional consequences.

The main technical variants include transthoracic and transhiatal approaches. The Ivor Lewis procedure uses an intrathoracic anastomosis, whereas the McKeown procedure includes a cervical phase with a cervical anastomosis, often selected to reduce the clinical impact of any leakage. The transhiatal approach avoids thoracotomy but limits upper mediastinal clearance and is more suitable for distal tumors in selected patients. Minimally invasive and robotic approaches have become established, with potential advantages in blood loss, recovery, and respiratory complications, provided that the team has adequate experience and the center treats high volumes. Determinants of outcome include margin quality, adequacy of lymph-node dissection, gastric-conduit perfusion, and the selected anastomotic technique, balancing the risks of leakage and stenosis.

In selected patients treated with neoadjuvant chemoradiotherapy and surgery, adjuvant immunotherapy may be indicated when residual pathological disease persists. Randomized studies have shown that a PD-1 inhibitor administered for a defined period after esophagectomy can prolong recurrence-free survival compared with observation. Candidate selection is based on response to preoperative therapy, pathological stage, and risk profile, while considering autoimmune comorbidities and potential immune-mediated toxicity.

For unresectable locally advanced tumors or patients who are not surgical candidates because of comorbidities, reduced cardiorespiratory reserve, or informed refusal, definitive chemoradiotherapy with curative intent is a recognized strategy. The most commonly used protocols combine cisplatin and 5-fluorouracil or carboplatin and paclitaxel with radiotherapy at total doses often between 50 and 60 Gy, adapting volumes and fractionation to disease extent and proximity to critical organs. For cervical or cervicothoracic lesions, where surgery may be highly mutilating and substantially affect phonation and swallowing, definitive chemoradiotherapy is frequently considered the treatment of choice. In cases of persistent or locally recurrent disease, salvage esophagectomy may be considered in selected patients, although it carries a higher risk of complications; in other cases, endoscopic local-control options may be used for superficial recurrences in patients who are not candidates for major surgery.

In recurrent or metastatic disease, treatment is mainly palliative and aims to prolong survival and maintain quality of life. Platinum- and fluoropyrimidine-based regimens, sometimes combined with taxanes, have historically been used, with irinotecan and other cytotoxic agents as later-line alternatives. The introduction of PD-1 inhibitors has substantially changed the landscape: phase III studies have documented survival benefits with nivolumab plus chemotherapy or ipilimumab and, in selected settings, with pembrolizumab and other agents, with a greater effect in subgroups with higher PD-L1 expression. Taxanes, irinotecan, and cytotoxic combinations remain available in later lines, selected according to tolerability, time to progression, and the individual clinical profile.

Alongside systemic therapies, management of mechanical complications, especially dysphagia, is central. Placement of self-expanding esophageal stents can rapidly restore transit, either as a bridge to curative-intent treatment or for palliation. Alternatively or in combination, palliative external-beam radiotherapy or endoluminal brachytherapy may reduce obstruction and improve swallowing. Selected endoscopic techniques, such as dilation or bleeding-control procedures, may be used while considering perforation risk and expected duration of benefit, with the choice guided by prognosis, stenosis location, and patient preferences.

The entire therapeutic pathway depends critically on nutritional support, prevention of toxicity, and symptom control. Many patients have protein-calorie malnutrition and sarcopenia, which reduce tolerance of surgery and chemoradiotherapy and increase the risk of complications. Early involvement of dietitians and metabolic-nutritional support teams enables individualized strategies including dietary reorganization, supplements, enteral nutrition, and, when necessary, parenteral nutrition. At the same time, hematological, gastrointestinal, cutaneous, and neurological toxicities require proactive management with antiemetic prophylaxis, targeted use of growth factors, organ monitoring, and early recognition of immune-mediated reactions. Pain, dysphagia, cough, and psychological burden require an integrated pharmacological and psychosocial approach with dedicated teams. At every stage of disease, palliative care is not limited to the terminal phase but is incorporated early for patients with complex symptoms or an unfavorable prognosis, with the aim of preserving autonomy, dignity, and quality of life throughout the course.

Follow-up and post-treatment surveillance of esophageal squamous cell carcinoma are structured phases of care aimed at detecting locoregional or distant recurrence early, identifying second primary tumors of the upper aerodigestive tract, monitoring late treatment complications, and ensuring nutritional, functional, and psychosocial support. Unlike prediagnostic screening, post-treatment follow-up is individualized according to the type of treatment, initial stage, response achieved, and the patient’s clinical condition, and requires multidisciplinary planning with periodic reassessment based on the clinical course.

In patients treated with curative endoscopic resection for superficial squamous cell carcinoma confined to the mucosa, follow-up centers on endoscopic surveillance. The aim is to detect local recurrence at the resection site and identify new dysplastic or neoplastic lesions in an esophagus often characterized by field cancerization. Endoscopic examinations are generally scheduled more frequently during the first few years, with targeted biopsies of suspicious areas and advanced imaging techniques such as Lugol chromoendoscopy or virtual chromoendoscopy. In the absence of suggestive findings, intensive radiological follow-up is not usually necessary and is reserved for the development of symptoms or unexplained clinical findings.

After curative-intent esophagectomy, with or without preoperative therapy, follow-up is multidimensional. During the first two or three years, when the risk of recurrence is greatest, clinical assessments are often scheduled every 3–6 months and include symptom evaluation, physical examination, assessment of nutritional status, and review of comorbidities. Contrast-enhanced computed tomography of the chest and abdomen is used at regular intervals to monitor for recurrence and metastases, whereas endoscopy is used selectively, particularly for dysphagia, bleeding, clinical suspicion of anastomotic stenosis, or radiological findings requiring clarification. In patients who have undergone cervical resections or procedures with potential recurrent laryngeal nerve involvement, follow-up includes functional assessment of phonation and swallowing, with speech and language therapists and rehabilitation teams involved when needed.

In patients treated with definitive chemoradiotherapy, follow-up requires particular attention because distinguishing complete response from residual disease and recurrence may be difficult. After treatment completion, initial response assessment is performed with CT and, in selected cases, 18F-FDG PET, while considering the risk of nonspecific uptake due to post-radiation inflammation. Endoscopy with targeted biopsies retains a crucial role in verifying local control, particularly when mucosal abnormalities or symptoms persist. In patients with a complete clinical response, clinical and endoscopic examinations are generally more frequent during the first few years, while radiological surveillance remains important for detecting distant recurrence.

A cross-cutting element of follow-up is surveillance for second primary tumors of the upper aerodigestive tract. Patients with prolonged tobacco and alcohol exposure have an increased risk of synchronous or metachronous neoplasms of the oral cavity, pharynx, larynx, and residual esophagus. Follow-up should therefore include careful clinical assessment of the head and neck region and, when symptoms or suspicious findings are present, targeted endoscopic examinations. In selected individuals, such as patients with a previous head and neck carcinoma, endoscopic surveillance of the esophagus may be considered even in the absence of symptoms within a structured clinical pathway.

Follow-up also includes management of functional and nutritional sequelae. After esophagectomy, functional dysphagia, bile reflux, dumping syndrome, early satiety, and chronic weight loss may develop. Nutritional monitoring, including assessment of weight, muscle mass, and biochemical parameters, is fundamental to preventing or treating malnutrition and sarcopenia. In patients who have received chemoradiotherapy, late toxicities must also be monitored, including esophageal stenosis, mediastinal fibrosis, radiation pneumonitis, and cardiac complications, which may appear months or years later.

The overall duration of follow-up is generally at least five years, with greater intensity during the first two or three years and progressively longer intervals in disease-free patients. Thereafter, in individuals at low risk of recurrence but with persistent risk factors, follow-up tends to focus more on comorbidities, functional sequelae, and prevention of additional clinically significant events, while maintaining attention to warning symptoms. In every case, follow-up should remain flexible and tailored to the individual patient, integrating oncological, nutritional, and quality-of-life considerations.

In summary, post-treatment follow-up of esophageal squamous cell carcinoma is not limited to radiological examinations but requires a coordinated approach combining oncological surveillance, detection of second primary tumors, and management of late complications, with the aim of preserving functional status and long-term quality of life as far as possible.

Long-term quality-of-life considerations in esophageal squamous cell carcinoma are central to comprehensive patient care and become increasingly important as survival improves. Even in the absence of active disease, many patients live for years with functional, nutritional, and psychological sequelae that substantially affect daily life. Quality of life should therefore be assessed systematically and continuously as an integral component of comprehensive care.

One of the most relevant domains is swallowing function. After esophagectomy, reconstruction of food transit produces profoundly altered digestive physiology, with possible residual dysphagia for solid foods, a sensation of slowed bolus passage, and a lasting need to modify food consistency and meal patterns. In patients treated with chemoradiotherapy, fibrosis and esophageal stenosis may cause chronic swallowing difficulties. Functional assessment and targeted rehabilitation promote better long-term adaptation.

Bile or acid reflux is a common disorder after surgery, with manifestations such as regurgitation, sleep disturbances, and chronic cough. Management is based mainly on dietary and behavioral measures, with lasting lifestyle changes that require appropriate educational and clinical support.

Postprandial metabolic disturbances, including manifestations of dumping syndrome, may limit autonomy and social life. Symptoms such as palpitations, sweating, abdominal pain, or reactive hypoglycemia require reorganization of eating habits, with small frequent meals and careful nutrient distribution, and therefore ongoing nutritional support.

Nutrition and body composition directly affect quality of life. Unintentional weight loss, reduced muscle mass, and malnutrition are common and are associated with greater frailty and reduced functional capacity. Longitudinal monitoring of weight, body composition, and nutritional intake, together with individualized interventions, is essential to preserve autonomy and well-being.

Treatment sequelae may also affect respiratory and vocal function. Reduced respiratory capacity, chronic cough, and persistent dysphonia affect communication, employment, and social relationships. A multidisciplinary rehabilitation approach can lessen the impact of these disorders and promote functional recovery.

The psychological and psychosocial sphere plays a decisive role. The often complex and invasive treatment pathway may leave lasting emotional consequences, including anxiety, depression, fear of recurrence, and altered body image. Dietary and functional limitations may reduce social participation and impair interpersonal relationships. Structured psychological support and ongoing communication with the care team promote better adaptation to survivorship.

Overall, long-term quality of life depends on the healthcare system’s ability to provide integrated care that combines clinical surveillance with management of functional, nutritional, and psychological sequelae. In this context, quality of life is a clinical outcome of primary importance and should be considered alongside traditional indicators when evaluating the overall success of treatment for esophageal squamous cell carcinoma.

Complications of esophageal squamous cell carcinoma arise from the interaction between disease progression, oncological treatments, and endoscopic procedures, creating a complex clinical picture that requires continuous surveillance and multidisciplinary management. From the early stages, narrowing of the esophageal lumen may cause progressive dysphagia, reduced caloric intake, and malnutrition, whereas the consequences of locoregional infiltration and systemic impairment predominate in advanced disease. Early assessment of nutritional and functional status is crucial because loss of lean mass and frailty increase the risk of infection and treatment-related toxicity.

Local tumor progression causes increasingly severe dysphagia, potentially leading to complete inability to eat, with a higher risk of aspiration and aspiration pneumonia, particularly in the presence of swallowing impairment or recurrent laryngeal nerve involvement. Invasion of adjacent structures may cause persistent chest pain, chronic cough, dysphonia, and dyspnea. The formation of esophagorespiratory fistulas is one of the most serious complications and is associated with recurrent pulmonary infections and high mortality. In more advanced cases, erosion of mediastinal vascular structures may cause massive fatal hemorrhage, while cachexia, venous thromboembolism, and paraneoplastic syndromes contribute to overall clinical deterioration.

Esophageal surgery carries a significant risk of complications. Respiratory complications, particularly pneumonia, are the leading cause of postoperative morbidity and mortality. Anastomotic leakage is one of the most feared events and may occur early because of perfusion problems or later in association with local infection. Late anastomotic strictures may require repeated endoscopic dilations, with a cumulative risk of perforation. Chylothorax, related to thoracic duct injury during lymph-node dissection, causes substantial fluid and protein losses. Postoperative arrhythmias, particularly atrial fibrillation, and recurrent laryngeal nerve injuries during extensive resections complete the spectrum of major surgical complications.

Chemoradiotherapy is associated with acute and late toxicities. Common manifestations include esophagitis and mucositis, which cause pain, severe dysphagia, and further deterioration of nutritional status. Cytopenias increase infectious and bleeding risks, whereas radiotherapy may cause radiation pneumonitis, mediastinal fibrosis, and pericarditis. Chronic esophageal stenosis may develop over time and, more rarely, esophagorespiratory or esophagoaortic fistulas, the latter often rapidly fatal. Cardiac and pulmonary involvement is more likely in patients with pre-existing comorbidities or high-dose treatment.

Immunotherapy may induce immune-mediated complications affecting several organs. The most clinically significant manifestations include immune-mediated pneumonitis, colitis, hepatitis, thyroid and adrenal endocrinopathies, dermatitis, and nephritis. Although rare, conditions such as immune-mediated myocarditis carry high mortality and require immediate recognition and treatment. Management of these toxicities requires close clinical and laboratory monitoring.

Endoscopic procedures used to control dysphagia or treat superficial lesions carry specific risks. Self-expanding stents may cause pain, migration, ulceration, perforation, or fistulas, particularly in esophagi with post-radiation fibrosis. Endoscopic dilation carries a risk of perforation that is higher in tight stenoses. Resection and ablation techniques may be complicated by bleeding, perforation, and late cicatricial stenosis.

Systemically, cancer cachexia, opportunistic infections, and thromboembolic events are major determinants of poor prognosis. Progressive functional decline requires a comprehensive approach that integrates symptom control, nutritional support, and, when indicated, palliative care at an early stage.

Effective management of complications is based on structured prevention, including early nutritional screening, optimization of respiratory function, pain control, physiotherapy, monitoring of comorbidities, and prompt recognition of signs of toxicity or infection. Integration of multidisciplinary expertise reduces the severity of adverse events, improves quality of life, and enables as many patients as possible to complete treatment pathways in the best possible clinical condition.